Metastatic esophagogastric cancer: Controversies, consensus, and new targets Book Section

  


Authors: Ku, G. Y.; Ilson, D. H.
Editors: Abutalib, S. A.; Markman, M.
Article/Chapter Title: Metastatic esophagogastric cancer: Controversies, consensus, and new targets
Abstract: This chapter presents a series of questions and answers on controversies, consensus, and new targets of metastatic esophagogastric cancer. It commences with a discourse on optimal first-line chemotherapy regimen for advanced esophagogastric cancer, and ends with the evaluated new targeted therapies. The chapter also discusses on whether first-line chemotherapy continued until progression or stopped after 4-6 months, data for second-line chemotherapy, and targeted therapies available for esophagogastric cancer. © 2014 John Wiley and Sons, Inc.
Keywords: targeted therapies; first-line chemotherapy; metastatic esophagogastric cancer
Book Title: Cancer Consult: Expertise for Clinical Practice
ISBN: 978-1-118-58921-2
Publisher: Wiley Blackwell  
Publication Place: Hoboken, NJ
Date Published: 2014-01-01
Start Page: 562
End Page: 566
Language: English
DOI: 10.1002/9781118589199.ch86
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84946433628&partnerID=40&md5=6d3f52d7686c37225de10a5ba6a51cd9
Notes: Book Chapter: 86 -- Export Date: 2 December 2015 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Geoffrey Yuyat Ku
    230 Ku
  2. David H Ilson
    433 Ilson
Related MSK Work